Simon is new FDA anti-inflammatory division director
This article was originally published in Pharmaceutical Approvals Monthly
Lee Simon, MD, will start Nov. 19 as director of Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, replacing Acting Director Jonca Bull, MD. Simon, an associate professor of medicine at Harvard Medical School, was a principal investigator and lead author of Celecoxib Long-term Arthritis Safety Study. He has served as a consultant to Lilly, Forest, Aventis and Pharmacia/Searle
You may also be interested in...
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.